Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
27 avr. 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Present at the 2022 ASCRS Annual Meeting
18 avr. 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
30 mars 2022 07h15 HE
|
Graybug Vision, Inc.
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy...
Graybug Vision to Host Virtual R&D Day on March 30, 2022
21 mars 2022 16h30 HE
|
Graybug Vision, Inc.
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments
10 mars 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug to Participate in Three Upcoming Medical and Investor Conferences
03 févr. 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
20 janv. 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 16h05 HE
|
Graybug Vision, Inc.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments
11 nov. 2021 16h04 HE
|
Graybug Vision, Inc.
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
01 nov. 2021 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...